Coherus Oncology, Inc. (NASDAQ:CHRS - Free Report) - Stock analysts at HC Wainwright cut their FY2030 earnings per share estimates for Coherus Oncology in a research report issued to clients and investors on Tuesday, November 10th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will earn $0.15 per share for the year, down from their previous estimate of $0.19. HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Coherus Oncology's current full-year earnings is ($0.83) per share.
Coherus Oncology (NASDAQ:CHRS - Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.03). The firm had revenue of $14.27 million for the quarter, compared to analysts' expectations of $15.90 million. Coherus Oncology had a negative return on equity of 274.46% and a negative net margin of 253.43%.
A number of other brokerages also recently issued reports on CHRS. Weiss Ratings downgraded shares of Coherus Oncology from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, November 10th. Wall Street Zen cut shares of Coherus Oncology from a "hold" rating to a "sell" rating in a research report on Saturday, November 14th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $11.00.
Read Our Latest Stock Analysis on Coherus Oncology
Coherus Oncology Stock Down 14.3%
CHRS opened at $0.41 on Thursday. The company has a debt-to-equity ratio of 2.08, a current ratio of 1.51 and a quick ratio of 1.45. The company's 50-day moving average is $1.01 and its 200 day moving average is $1.45. Coherus Oncology has a fifty-two week low of $0.41 and a fifty-two week high of $2.62. The firm has a market capitalization of $63.33 million, a P/E ratio of -0.42 and a beta of 1.03.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the stock. Spark Investment Management LLC purchased a new stake in shares of Coherus Oncology during the 2nd quarter worth approximately $25,000. Cetera Investment Advisers bought a new stake in shares of Coherus Oncology in the 1st quarter worth approximately $54,000. The Manufacturers Life Insurance Company purchased a new position in Coherus Oncology in the second quarter valued at approximately $54,000. Dimensional Fund Advisors LP purchased a new position in Coherus Oncology in the first quarter valued at approximately $60,000. Finally, Hsbc Holdings PLC purchased a new position in Coherus Oncology in the second quarter valued at approximately $131,000. 72.82% of the stock is owned by institutional investors.
Coherus Oncology Company Profile
(
Get Free Report)
Coherus Oncology, formerly Coherus BioSciences, is a biopharmaceutical company focused on developing and commercializing cancer treatments. Its portfolio includes LOQTORZI (toripalimab-tpzi), an immune checkpoint inhibitor that targets PD-1 and is approved in the United States for certain patients with nasopharyngeal cancer. The company is also advancing a pipeline of investigational immuno-oncology medicines. Coherus historically built its business around biosimilar medicines before shifting its focus to oncology.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Coherus Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coherus Oncology wasn't on the list.
While Coherus Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.